Synthego, based in Redwood City, California, is a genome engineering company specializing in CRISPR solutions that enable accelerated life science research and therapeutic development. Founded in 2012 by Paul and Michael Dabrowski, former SpaceX engineers, Synthego has established itself as a leader in precision genome engineering, leveraging machine learning and automation to drive advancements in biotechnology. To date, the company has raised approximately $472.25 million over several funding rounds.
Attribute | Information |
---|---|
Founding Date | 2012 |
Headquarters | Redwood City, California, USA |
Founders | Paul Dabrowski, Michael Dabrowski |
Revenue | $75 million (as of early 2025) |
Profits | N/A |
Key Investors | Perceptive Advisors, AAF Management Ltd., RA Capital Management |
Industry | Genome Engineering, Biotechnology |
Number of Employees | Approximately 201 |
Synthego was established in 2012 by brothers Paul and Michael Dabrowski with a vision to revolutionize genome engineering. Drawing on their background at SpaceX, they aimed to integrate their engineering expertise into the burgeoning field of CRISPR technology. Starting from a modest setup, the company quickly gained traction by partnering with leading biotech firms and research institutions, propelling it to the forefront of genome editing innovation. Early success was bolstered by strategic investments and technological advancements that aligned with the growing demand for CRISPR-based research tools.
Synthego's business model revolves around providing comprehensive genome engineering solutions. The company offers a range of products, including synthetic RNA designed for CRISPR applications, catering to both research and clinical markets. Synthego's major achievements include:
Synthego continues to operate within the genome engineering sector, focusing primarily on providing CRISPR solutions to pharmaceutical, biotechnology companies, and academic institutions. The company maintains a strong presence in research and development, driven by its vertical integration of proprietary bioinformatics, software, and hardware. Despite recent financial struggles that led to its bankruptcy filing, Synthego remains a pivotal player in the biotechnology landscape, leveraging its advanced CRISPR platforms to sustain its market position.
Synthego has played a significant role in advancing the field of genome engineering, particularly with its contributions to CRISPR technology. Despite facing financial difficulties, the company's strategic initiatives and partnerships underscore its commitment to innovation and leadership in biotechnology. As Synthego navigates its restructuring phase, its foundational strengths in technology and collaboration are likely to guide its future trajectory in the genome engineering industry.